Xerox (XRX): A 4-Year Call Option on a Shrinking Print Business — Oct 2026 Valuation

Valuation by Damodaran | psind707 | Oct 11, 2026 | Price $2.75 (Oct 9 close) | Next catalyst: Q3 results Oct 29, 2026

1. The thesis in four lines

• On EV multiples, Xerox looks in line with print peers (6.1x clean EBITDA vs a 7.0x peer median). That comparison is misleading because Xerox carries 5.2x net leverage vs 0.7x to 2.4x for peers.
• The headline $250M 2026 FCF guide is flattered by a liquidating lease book (receivables down $406M in 12 months) and a one-off $80M tariff-refund sale. Strip both out and core equity FCF is about negative $44M.
• With $5.6B of face claims against a $361M market cap, the equity is best valued as a call option on the enterprise (Damodaran's distressed-equity method), with a 4.0-year face-weighted duration.
• The bond market agrees with the equity being thin: Xerox repurchased its own debt at about 50 cents on the dollar in H1 2026, and its 2030 notes step up to a 16.75% coupon.

2. Business snapshot (Q2 2026)

3. The hidden issue: a liquidating lease book

Xerox Financial Services (XFS) used to fund equipment leases on its own balance sheet. Origination has fallen and receivables are being sold to third-party funding partners, so the book is running off and the cash shows up in operating cash flow.

The cash-flow line "decrease in finance receivables" was $489M in FY2025 and $434M trailing twelve months. The 10-K states that the 2026 operating cash flow guide reflects an overall reduction in finance receivables. My interpretation: that cash is the return of capital from a shrinking asset, matched by repayment of financing debt, and should not be capitalized as recurring free cash flow.

4. Claims on the enterprise ($M, Jun 30, 2026)

5. Debt maturity wall

Liquidity is adequate near term: $495M cash plus $276M net availability on an undrawn $425M ABL revolver (matures May 2028). There is no default trigger before 2028. The problem is refinancing $3B between 2028 and 2030 at the coupons the market now demands.

6. Intrinsic value: DCF plus equity-as-option

Discount rate. Risk-free 5.22% (10-year Treasury, Oct 8, 2026). Damodaran US Office Equipment and Services unlevered beta 1.04 (cash-corrected, Jan 2026), giving an unlevered cost of capital of 9.9%. Pre-tax cost of debt 11%. WACC 10.5% in the base case, 11.5% bear, 9.5% bull. Raw regression beta (2.46) is not used, per house rules.

Option inputs. Firm value = operating EV + cash + receivables. Strike = $5,562M face claims. Duration 4.0 years (face-weighted maturity ladder). Firm volatility 25%. Payout yield 7% (cash paid out to claimholders each year). Warrants are deducted from the option value.

Why negative terminal growth. Office print is a structurally declining market (pro forma revenue down 6.5%). Under the aging-in-dog-years framework a Gordon perpetuity at positive growth is inappropriate here.

Reverse DCF. $2.75 implies an operating EV of about $3.0B, 21% above the base case and close to the bull case. That is 4.2x clean EBITDA on an operating basis.

7. Peer-relative valuation

Prices are Oct 9, 2026 closes (Kabutan for Japanese names, Massive for PBI). EV = market cap + total debt minus cash. XRX shown on 2026E clean EBITDA of $720M (adj. operating income plus depreciation, less SBC and recurring restructuring).

* Estimated: stale consensus scaled to the new price. Damodaran US industry average EV/EBITDA is 10.0x (Jan 2026), but every core print peer trades below it.

Consistency gate. DCF ($1.62) and the core-median comp diverge by more than 2x before pension. The explanation is leverage: peer multiples come from balance sheets with 0.7x to 2.4x leverage and no 2028 to 2030 refinancing wall. On the only leverage-matched comp (Konica Minolta), Xerox equity is negative under every pension treatment. Once the pension deficit is included, the peer median gives $0.41, below the DCF. The gate is passed with this explanation.

8. Pricing section

Why AVOID rather than SELL. The value label is OVERVALUED, but a short faces a crowded borrow (16 days to cover), an accumulating activist with a credible monetization angle for XFS, and a 2-year warrant overhang that the company can reprice at its discretion. No position is the right expression.

9. What would change the call

• Upside: an XFS sale or JV at or above book, plus evidence that core FCF (ex-runoff) turns positive; a refinancing of the 2028 to 2029 maturities below 10%.
• Downside: another operating cash flow guide cut on Oct 29; runoff slowing without a matching EBITDA lift; a coercive debt exchange that dilutes equity.
• Re-run due after Q3 (Oct 29, 2026) and Q4 results, per the post-mortem cadence.

10. Data notes

• Verified from SEC filings: debt ladder, receivables, pension, preferred, warrants, Form 4s, 13D/13G filings. Peer prices are Oct 9 closes.
• Not verified: H2 2026 runoff (assumed $300M for FY2026); Lexmark synergies realized in 2026 (the FY2025 10-K cites more than $500M of cumulative gross run-rate savings incl. integration); Japanese peer balance sheets are June-quarter data, with results due Oct 27 to Nov 6; peer forward P/Es other than HPQ.
• An earlier ten-name screen (Oct 10) put XRX at $1.72. This standalone report supersedes it.
• This is research, not investment advice.

Sources: Xerox Q2 2026 10-Q; FY2025 10-K; Q1 2026 10-Q; Q2 2026 earnings release (8-K Ex. 99.1); SEC EDGAR Form 4, 13D and 13G filings; stockanalysis.com; Kabutan; Massive (Polygon) market data; FINRA short interest; Damodaran Online (Betas, EV/EBITDA, Jan 2026).